Canagliflozin-d<sub>4</sub>

Canagliflozin-d4

CAT N°: 25223
Price:

779.00 662.15

Canagliflozin-d4 is intended for use as an internal standard for the quantification of canagliflozin (Item No. 11575) by GC- or LC-MS. Canagliflozin is an inhibitor of sodium-glucose cotransporter 2 (SGLT2; IC50 = 2.2 nM) that less potently blocks SGLT1 (IC50 = 910 nM).{18745} Canagliflozin is orally bioavailable and lowers plasma glucose by lowering the renal threshold for glucose and increasing urinary glucose excretion in animals.{18745,33510} Formulations containing SGLT2 inhibitors, including canagliflozin, have been used to treat type 2 diabetes mellitus.{33509}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (1S)-1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl-2,3,5,6-d4)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol
  • Correlated keywords
    • deuterated deuterium SGLT-1 2 T2D JNJ-24831754 TA-7284 JNJ24831754 TA7284
  • Product Overview:
    Canagliflozin-d4 is intended for use as an internal standard for the quantification of canagliflozin (Item No. 11575) by GC- or LC-MS. Canagliflozin is an inhibitor of sodium-glucose cotransporter 2 (SGLT2; IC50 = 2.2 nM) that less potently blocks SGLT1 (IC50 = 910 nM).{18745} Canagliflozin is orally bioavailable and lowers plasma glucose by lowering the renal threshold for glucose and increasing urinary glucose excretion in animals.{18745,33510} Formulations containing SGLT2 inhibitors, including canagliflozin, have been used to treat type 2 diabetes mellitus.{33509}

We also advise you